Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program FDAThe U.S.RegulatoryGene TherapyRead full story pharminent April 23, 2026 (Last updated: April 24, 2026) FDA The U.S. RegulatoryGene TherapyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug CoverageNext: FDA approves Regeneron’s hearing loss gene therapy Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
